Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue SUPPL. 1, 2001, Pages

  Haubrich, R ^a   Demeter, L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genotype; Phenotype; Predictors of response; Resistance; Virologic response

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; NELFINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MEDICAL DECISION MAKING; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; MICROBIOLOGICAL EXAMINATION; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; STANDARD; VIROLOGY;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GUIDELINES; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035280931     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103011-00006     Document Type: Review

References (31)

1. Low rate of maximal suppression of HIV-1 RNA in a trial of RNA monitoring in clinical practice
2. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS Clinic: Response to both initial and salvage therapy
3. Patterns and prognostic implications of prior antiretroviral therapy (ART) at UCSD Owen Clinic: 1996-1999
4. HIV-I genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
5. Baseline HIV drug resistance profiles predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
6. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
7. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort
8. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using standardized data analysis plan
9. HIV-1 baseline genotype/phenotype and virological response following salvage therapy with Ziagen (abacavir, ABC), amprenavir (APV), and Sustiva (efavirenz, EFV)
10. Multivariate analysis of predictors of response to abacavir: Comparison of prior antiretroviral therapy, baseline HIV RNA, CD4 count and viral resistance
11. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372)
12. Virological response to nelfinavir, efavirenz, or both in patients with >4 years of previous nucleoside RT inhibitors in ACTG 364
13. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort
14. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
15. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
16. Final Results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic anti-retroviral resistance testing (GART) in patients failing antiretroviral therapy
17. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel
18. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA 3001)
19. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients
20. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
21. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
22. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
23. Transmission and prevalence of HIV resistance among treatment-naive subjects
24. HIV-1 drug resistance in newly infected individuals
25. Transmission of antiretroviral-drug-resistant HIV-1 variants
26. Prevalence of baseline drug resistance mutations in primary HIV infection patients from the QUEST study
27. Vertical transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors
28. Novel amino acid change influencing susceptibility to nevirapine detected in primary HIV infection
29. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors